Ceapro Inc V.CZO

Buzz on the Bullboards: Volatility persists in the face of economic indicators

[prophetoffactz]

"As previously disclosed, subject to obtaining all required approvals and satisfying all required conditions, the Transaction is expected to close on or about June 3, 2024."

[prophetoffactz]

Imagine if you could predict those vulnerable 10 years in advance and provide them with a safe and well tolerated neutraceutical option to help address heart inflammation.

[prophetoffactz]

The Lancet Publishes Results from World's Largest Coronary CT Registry Showing New AI Technology Can Predict Cardiac Events Due to Coronary Inflammation At Least 10 Years in Advance   

[Jonathon Brown]

Canada’s main stock index struggled and the NASDAQ hit a high, demonstrating a continued appetite for tech stocks amidst market volatility. read article.

[prophetoffactz]

Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date   T.AEZS | 1 minute ago TORONTO

[Hopeforthebest]

Reduced sales, reduced margins, increased costs, increased lost$$$$ in Q1-2024 compared to Q1 - 2023. at this rate both Aezs and zo will be out of cash by mid 2025 .his si what a gagnon run set

[Tencents]

It would seem czo will have a cash crunch in the next 6 months - based on current flows and probable merger integration / redundancy costs - cash less than 5 m compared to 12 m q2 2023  while its

[prophetoffactz]

EOM

[lscfa]

Base biz barely cash flow positive   CFO b/f legal & R&D   439,733 Q1 24

[prophetoffactz]

There's so much they aren't saying in this news release. Maybe more detail once the merger closes. What about the dry powder with Symrise and the malted avenanthramide evaluation? What is the

[lscfa]

Germany sales permanently lower?        US Germany China Other

[prophetoffactz]

They may be waiting for the completion of the merger expected around June 3 for a more fulsome update. Two months into Q2 they say "One major customer is gradually resuming ordering..."

[lscfa]

Drunken sailor spending....     Revenues Gross profit Gross margin Cash flow ops

[PressRelease]

– Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology – Q1 2024 sales of $2,800,000 vs $3,500,000 in Q1 2023– Announcedapproval by...read article.

[prophetoffactz]

until the expected closing of the merger. Interesting timing. AEZS's diagnostic test trial is expected to be completed in the next month with topline results in Q3. This sets the stage for

[Apostata]

Strangely high volume so far today.